Download pptx - Clinical Data Capture

Transcript
Page 1: Clinical Data Capture

Clinical Data CaptureCBI Conference; August 20, 2013

Page 2: Clinical Data Capture

Speakers

Ben Yao

Associate

Huron Life Sciences

Manny Tzavlakis

Managing Director

Huron Life Sciences

© 2013 Huron Consulting Group. All Rights Reserved. Proprietary & Confidential.

Joseph Morrell

Manager

Huron Life Sciences

Page 3: Clinical Data Capture

Agenda

• Considerations for Capturing Clinical Data from Third Parties

• Using Technology to Facilitate Data Capture

• New Possibilities

• Q&A

© 2013 Huron Consulting Group. All Rights Reserved. Proprietary & Confidential.

Page 4: Clinical Data Capture

Considerations for Capturing Clinical Trial Payment Data

Page 5: Clinical Data Capture

© 2013 Huron Consulting Group. All Rights Reserved. Proprietary & Confidential.

Capturing clinical data from third parties: Contract Research Organizations (CROs), Academic Research Organizations (AROs), Site Management Organizations (SMOs), is a challenge for many manufacturers. Considerations for successful clinical spend data capture:

Establish

Business

Requireme

nts

•Work with internal compliance/legal to determine baseline requirements for capture of clinical trial payment data.

•Confer with relevant functional units (e.g. various therapeutic areas, global vs. US, etc.) to determine data formats across units as well as additional data to be gathered for business

purposes.

Finalize

Technical

Requireme

nts

•Determine which systems will be impacted by the clinical trial business requirements.

•Document technical requirements for existing (e.g. Accounts Payable, Customer Master, Reporting Warehouse) and new (e.g. CRO data capture system) systems.

Develop

Business

Processes

•Identify resources to provide CROs with updated trial information and to manage error resolution.

•Update business processes to ensure that all necessary data are included in site agreements or other study startup documentation.

•Ensure that resources and processes for reviewing data and managing disputes are in place.

Considerations for Capturing Clinical Trial DataDEVELOPING REQUIREMENTS AND UPDATING PROCESSES

Page 6: Clinical Data Capture

© 2013 Huron Consulting Group. All Rights Reserved. Proprietary & Confidential.

Considerations for Capturing Clinical Trial DataDEVELOPING REQUIREMENTS AND UPDATING PROCESSES

• When developing requirements for capturing clinical trial payment aggregate spend data, one of the primary goals should be to enhance data consistency across all third parties and internal Accounts Payable.

• Consistent identification of investigators, sites, trials, and compound codes will be essential for efficient generation of aggregate spend reports.

Page 7: Clinical Data Capture

© 2013 Huron Consulting Group. All Rights Reserved. Proprietary & Confidential.

Considerations for Capturing Clinical Trial DataDEVELOPING REQUIREMENTS AND UPDATING PROCESSES

When developing business and technical requirements, a manufacturer should consider that different business units may:• Have different formats for data such as site number, protocol/trial number, etc., or may or

may not use some of these data elements consistently• In limited cases such as certain post-marketing studies, have more than one principal

investigator• Utilize different types of healthcare professionals (e.g. doctors, PhDs, dieticians, or others)

as investigators• Issue payments to investigators via investigator sponsored trial payments

When developing processes, consider that:• Different business units may contract with sites in different ways (e.g. directly or via CROs

or other contracting vendors)• Processes must be established to account for when a principal investigator at a given study

site changes

Page 8: Clinical Data Capture

Using Technology to Facilitate Data Capture: One

Solution

Page 9: Clinical Data Capture

© 2013 Huron Consulting Group. All Rights Reserved. Proprietary & Confidential.

Using Technology to Facilitate Data CaptureDEVELOPING ONE SOURCE OF CLINICAL TRIAL SITE PAYMENT DATA

In general, clinical trial site payment data will be housed in a variety of systems across:

Manufacturers should consider deploying one system to consolidate this data to promote:• The data consistency described previously.• The ability to aggregate, review, and analyze data by investigator, site, or compound.• The ability to monitor the compliance of CROs with the manufacturer’s reporting deadlines.• A single source of clinical trial payment data for integration into the manufacturer’s existing

aggregate spend reporting architecture.

Page 10: Clinical Data Capture

© 2013 Huron Consulting Group. All Rights Reserved. Proprietary & Confidential.

Using Technology to Facilitate Data Capture

Principles of the CRO Data Capture System

• Develop standard Excel/flat file templates that are acceptable to all business and geographic regions; deploy this template to all CROs and mandate compliance with the data requirements.

• Establish a consistent reporting and error resolution schedule across all CROs.• Validate data against business rules prior to processing into the aggregate spend architecture.• Provide a single source of clinical trial site payment data for aggregate spend reporting

purposes.

BENEFITS OF CENTRALIZED CLINICAL TRIAL PAYMENT DATA

Page 11: Clinical Data Capture

Using Technology to Facilitate Data Capture

• If a CRO submits a record that does not match your master list of:

• Trials

• Compounds

• Investigators

• Sites

That record will be returned to the relevant CRO for correction. This

validation will help reduce data errors within a manufacturer’s aggregate

spend architecture.

• The CRO Data Capture System will also monitor to ensure that CROs submit

data in accordance with the manufacturer’s guidelines. CROs that do not

meet timing guidelines will be alerted by the System.

BENEFITS OF CENTRALIZED CLINICAL TRIAL PAYMENT DATA: VALIDATION

Page 12: Clinical Data Capture

Using Technology to Facilitate Data CaptureOPTIONAL CUSTOMER STANDARDIZATION AND MATCHING FUNCTIONALITY

• If a CRO submits a record that does not match your master list of:

• Investigators

• Sites (Organizations)

That record can be automatically standardized and matched against your

master list and either assigned to an existing master unique ID or sent for

manual resolution.

• CROs are notified of resolved records to reduce subsequent errors.

• Records that are of very low quality will be returned to the CRO for correction

and re-submission.

• Customer matching will reduce the volume of errors going back to the CROs

when a unique ID has not been provided

Page 13: Clinical Data Capture

Key Challenges & Best PracticesCAPTURING CLINICAL PAYMENTS

© 2013 Huron Consulting Group. All Rights Reserved. Proprietary & Confidential.

Selected Key Challenges

Navigation of the complexity of reporting relationships (e.g. “research” chain scenarios with downstream payments)Engagement with third parties who utilize non-traditional research methods (e.g. SMOs and AROs); getting buyoff and cooperation with frequent and accurate reporting Integration of third party systems, data structure and processes to align with reporting process

Best Practices

Data capture in upstream business processes to accommodate consistent business rules at a later stage

Creation and utilization of a centralized customer master to track both HCP and HCO spend across the organization; shared customer IDs with third party partnersEarly and frequent onboarding for third party partners to ensure buy-in, organizational support, and solution identification. Continuous and open communication amongst stakeholders

Page 14: Clinical Data Capture

New Possibilities

Page 15: Clinical Data Capture

• Healthcare Practitioners (HCPs) involved in Clinical Trials are expected to decrease between 25 – 50% due to the Open Payments Act according to ASCO

• With limited Clinical Key Opinion Leaders (KOLs), manufacturers will be competing for a smaller number of investigators and specialists

• Utilizing the data store created by capturing Clinical Transparency information, manufacturers can build new data models to determine where KOLs can be more effectively utilized within an organization, particularly in various specialty markets• Clean data is the key to this – the more accurate the data in a

Clinical reporting data store, the more effective a manufacturer can be in targeting Clinical KOLs

© 2013 Huron Consulting Group. All Rights Reserved. Proprietary & Confidential.

New PossibilitiesAFTERMATH OF A CLINICAL TRANSPARENCY PROGRAM

Page 16: Clinical Data Capture

© 2013 Huron Consulting Group. All Rights Reserved. Proprietary & Confidential.

New PossibilitiesAFTERMATH OF A CLINICAL TRANSPARENCY PROGRAM

16© 2013 Huron Consulting Group. All Rights Reserved. Proprietary & Confidential.

Network analysis of 1,000 authors

who represent the main core of

published research in

specialized CNS

(For illustrative purposes only. Not final product.)

Page 17: Clinical Data Capture

© 2013 Huron Consulting Group. All Rights Reserved. Proprietary & Confidential.

New PossibilitiesAFTERMATH OF A CLINICAL TRANSPARENCY PROGRAM

Heat mapping: Identify large

concentrations of HCPs,

HCOs and research sites

along with reported spend

Page 18: Clinical Data Capture

Questions?


Recommended